Screener
Theravance Biopharma TBPH Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development (1) | 5,829 | 11,452 |
| Selling, general and administrative (1) | 17,720 | 18,370 |
| Restructuring expenses (1) (2) | 3,633 | — |
| Total expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Loss before income taxes | (6,470) | (14,138) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's total operating expenses?
- Theravance Biopharma (TBPH) reported total operating expenses of $27.18M in Q1 2026.
- How has Theravance Biopharma's total operating expenses changed year-over-year?
- Theravance Biopharma's total operating expenses decreased by 8.9% year-over-year, from $29.82M to $27.18M.
- What is the long-term trend for Theravance Biopharma's total operating expenses?
- Over 4 years (2021 to 2025), Theravance Biopharma's total operating expenses has grown at a -22.8% compound annual growth rate (CAGR), from $313.1M to $111.07M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Theravance Biopharma's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude